ClinicalTrials.gg
Active, not recruitingNCT04161898SELECT-TAKUpdated Feb 18, 2026

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

A Phase 3 interventional study of Upadacitinib and Placebo for Upadacitinib in Takayasu Arteritis (TAK), sponsored by AbbVie. Active, not recruiting at 48 sites in 6 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.

02

Conditions studied

  • Takayasu Arteritis (TAK)

Browse trials for

Keywords

  • Takayasu Arteritis (TAK)
  • Upadacitinib
  • Placebo
  • Corticosteroid
  • Prednisolone
03

In context

Takayasu Arteritis

79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.

This study's planned enrollment of 56 is above the median of 50 across 37 interventional studies indexed under Takayasu Arteritis.

Browse Takayasu Arteritis studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be at least 18 years of age (at least 15 years of age in Japan)
  • Clinical diagnosis of TAK and fulfilling the Japanese Guidelines for Management of Vasculitis Syndrome 2017 criteria.
  • Participant must have experienced a relapse of TAK within 12 weeks of Baseline despite being on treatment with oral .
  • Participants must be in remission and on a stable corticosteroid dose prior to Baseline.

Exclusion criteria

Exclusion Criteria:

  • Treatment with an interleukin-6 (IL-6) inhibitor or Janus Kinase (JAK) inhibitor (including but not limited to tocilizumab, sirukumab, sarilumab, upadacitinib, tofacitinib, baricitinib, ruxolitinib, peficitinib, and filgotinib) within 4 weeks of Baseline.
  • Current use of immunomodulators other than .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Arm 2: Placebo for Upadacitinib

    Participants will be administered placebo once daily (QD) along with prednisolone.

    Drug: Upadacitinib · Drug: Placebo for Upadacitinib · Drug: Prednisolone

  • Experimental
    Arm 1: Upadacitinib

    Participants will be administered updadacitinib once daily (QD) along with prednisolone.

    Drug: Upadacitinib · Drug: Prednisolone

Interventions

  • Upadacitinib will be administered as oral tablet

    Also known as: ABT-494, RINVOQ

  • DrugPlacebo for Upadacitinib

    Placebo for upadacitinib will be administered as oral tablet

  • Prednisolone will be administered as oral tablet

06

What researchers measure

Primary outcomes

  1. Time to First Relapse of Takayasu Arteritis (TAK) From Baseline through End of the Double-Blind (DB) Period

    Relapse of TAK is defined as the presence of signs or symptoms as judged by the investigator for at least 2 of the following categories: objective systemic symptoms, subjective systemic symptoms, elevated inflammation markers, vascular signs and symptoms, or ischemic symptoms OR where the criteria are met based on one category per protocol definition of relapse of TAK.

    Time frame: Up to occurrence of 40 events (approximately 52 months)

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 58 months

Secondary outcomes

  1. Time to First Relapse of Takayasu Arteritis (TAK) by Kerr Criteria From Baseline through End of the DB Period

    Kerr criteria for relapse are defined as the presence of signs or symptoms as judged by the investigator for at least 2 of the following categories: objective or subjective systemic symptoms, elevated inflammation markers, vascular or ischemic signs and symptoms, or worsening in imaging assessment due to TAK.

    Time frame: Up to occurrence of 40 events (approximately 52 months)

  2. Time to Worsening of Imaging Assessment Due to Takayasu Arteritis (TAK) From Baseline through End of the DB Period

    Imaging with computed tomography angiogram (CTA).

    Time frame: Up to occurrence of 40 events (approximately 52 months)

07

Study locations

48 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Aug 2028, 102 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 13, 2019
StartActual
Feb 4, 2020
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04161898
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2019
Start date
Feb 4, 2020
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Feb 18, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion